Josselin Caradec’s Post

BGV (BioGeneration Ventures) portfolio company Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of dosing in the repeat dose stage of its Phase 1 trial for its lead drug candidate CIT-013. The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial is investigating the safety and tolerability of repeat dosing in 9 patient volunteers with rheumatoid arthritis (RA) and 3 healthy volunteers. All trial participants have been enrolled and successfully completed dosing. Results are anticipated in Q4 2024, which, if positive, would lay the groundwork for the initiation of Phase 2a trials. Click on the following link to learn more: https://lnkd.in/ebkkfhTD #portfoliocompanynews #biotech #lifesciences #BGV #researchanddevelopment Daniela Couto

Let’s talk with a drink in your hand about immunogenicity risk assessment 🥂 See you - poster number 185

NEW EPISODE! Predicting flares in those being weaned off from biologic disease-modifying antirheumatic drug therapy can make the process of successfully tapering more than challenging. Our latest guest, Dr. Paul Emery, and his team may have discovered some predictors, adding some much-needed guidance. LISTEN HERE for more → https://acr.tw/3yvKSVn

It was a pleasure to be part of this year’s RAS-Targeted Drug Development Summit, joining peers across the sector to discuss the exciting potential of targeted protein degradation (#TPD) to tackle RAS pathway– here’s what I took from it:   1.     Since TPD was first applied to drug discovery, we have made significant progress. There are multiple potential advantages of protein degraders over inhibitor-based approaches to be confirmed at clinical stage, as well as potential issues we need to solve as a modality. 2.     There is no ‘one-size-fits-all’ in modality selection. Selecting the best approach for the disease and underlying biology being targeted is key. Both monovalent and bivalent molecules have pros and cons. 3.     More must be done if we are to maximize the potential of TPD for patients. Deepening our understanding of potential resistance mechanisms will help us refine our patient populations and combination strategies. At Astellas, we are deeply committed to advancing TPD, a modality we believe could redefine what’s possible in treating some of the world’s most devastating diseases – if you are interested in partnering with us, please reach out! #ScienceFirstForPatients #ChangingTomorrow https://lnkd.in/gaFBnmgV

New blog today showing off a use case written by Jessica, our Head of Business Development! In this example of how we work with customers, Bridge Informatics helped a pharmaceutical company perform strain-level bacterial classification (strain abundance analysis) for regulatory approval of their new immunotherapy product by analyzing whole genome sequencing data, leading to the identification of a predominant bacterial strain and speeding up the product development timeline. Let us know if you need support on a similar project! #bioinformatics #pharma #WGS

When our client needed to perform strain-level bacterial taxonomic classification as part of an essential component for regulatory approval of their new immunotherapy product, we quickly leveraged our team's expertise in #wholegenome #metagenomic #sequencing analysis, contributing to a smooth FDA approval process. Read the full case study on our blog: https://lnkd.in/efBxEQug #bioinformatics #genomics #pharma #regulatoryaffairs

In this latter half of 2024, following a hopeful uptick for the biotech industry in the first half, it’s more important than ever to stay on top of the quickly evolving news. Some of the most crucial developments to keep up with are the approaching FDA approval dates, which provide insight into the industry’s outlook for the rest of the year and into 2025. Check out a rundown of upcoming decision dates in the third quarter of 2024 here: https://loom.ly/j4NaDaw #BiotechNews #FDADecisionDates #BiopharmaNews #PDUFAs #TheBioHireJournal

We are thrilled to have been selected as a Fierce 15 Biotech Company! As our President and CEO Nancy Whiting noted: "It truly has been a transformative time for Recludix. We are the first company to successfully drug SH2 domains, exciting targets that are critical in mediating protein-to-protein interactions in many diseases. Our innovative oral small molecule inhibitors are based on our proprietary platform, which integrates custom DNA-encoded libraries, parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. This cutting-edge platform led to a strategic collaboration with Sanofi to advance a novel oral STAT6 inhibitor in multiple immunological and inflammatory indications, which included a total of $125 million in near-term payments and more than $1.2 billion in potential future milestones, while having an option to participate in an equal profit-sharing arrangement in the U.S. Additionally, we have identified highly potent, selective and orally bioavailable STAT3 inhibitors in our wholly-owned STAT3 program. We are excited to advance these molecules towards the clinic, as STAT6 and STAT3 activation is found in multiple disease pathways.” Read about the recognition: https://lnkd.in/eXVdVv4z

Thoughts on this? >> Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #pharma #productmarketing

There is a lot riding on the outcome of Amgen's Phase 2 study for its #obesity treatment MariTide. Here's what else is in STAT's quarterly biotech scorecard... 📈 Novo Nordisk will report results of a Phase 3 study involving its #obesitydrug candidate CagriSema before the end of this year. 📈 Vertex Pharmaceuticals’ next big growth opportunity is the non-opioid pain drug VX-548, or suzetrigine. An FDA decision is expected on Jan. 30. 📈 Alector is targeting #Alzheimers disease differently, with a drug intended to enhance the activity of a type of immune cell in the brain. Read more: https://trib.al/W1RBRjq